EUVIMEDEUVIMED entdecken
Crossref

Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models

Aysha S Ansari, Remant K C, Luis C Morales, Mohammad Nasrullah, Daniel Nisakar Meenakshi Sundaram, Cezary Kucharski, Xiaoyan Jiang, Joseph Brandwein, Hasan Uludağ

Journal of Controlled Release · 2024

DOI: 10.1016/j.jconrel.2024.02.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Aysha S Ansari und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton T6G 1H9, Alberta, Canada. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Aniline Compounds, Pyrazines. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: CIHR, Canadian Institutes of Health Research, Alex's Lemonade Stand Foundation for Childhood Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical development of tyrosine kinase inhibitors (TKI) has led to great strides in improving the survival of chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) patients. But even the new generation TKIs are rendered futile in the face of evolving landscape of acquired mutations leading to drug resistance, necessitating the pursuit of alternative therapeutic approaches. In contrast to exploiting proteins as targets like most conventional drugs and TKIs, RNA Interference (RNAi) exerts its therapeutic action towards disease-driving aberrant genes. To realize the potential of RNAi, the major challenge is to efficiently deliver the therapeutic mediator of RNAi, small interfering RNA (siRNA) molecules. In this study, we explored the feasibility of using aliphatic lipid (linoleic acid and lauric acid)-grafted polymers (lipopolymers) for the delivery of siRNAs against the FLT3 oncogene in AML and BCR-ABL oncogene in CML. The lipopolymer delivered siRNA potently suppressed the proliferation AML and CML cells via silencing of the targeted oncogenes. In both AML and CML subcutaneous xenografts generated in NCG mice, intravenously administered lipopolymer/siRNA complexes displayed significant inhibitory effect on tumor growth. Combining siFLT3 complexes with gilteritinib allowed for reduction of effective drug dosage, longer duration of remission, and enhanced survival after relapse, compared to gilteritinib monotherapy. Anti-leukemic activity of siBCR-ABL complexes was similar in wild-type and TKI-resistant cells, and therapeutic efficacy was confirmed in vivo through prolonged survival of the NCG hosts systemically implanted with TKI-resistant cells. These results demonstrate the preclinical efficacy of lipopolymer facilitated siRNA delivery, providing a novel therapeutic platform for myeloid leukemias.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteAniline CompoundsPyrazinesHumansAnimalsMiceRNA, Small InterferingFusion Proteins, bcr-ablOncogenesModels, AnimalProtein Kinase InhibitorsDrug Resistance, Neoplasm

Stichwörter der Autor:innen

Lipopolymers for siRNA deliveryMyeloid leukemia therapyRNAi therapysiRNA delivery

Substanzen

RNA, Small InterferinggilteritinibFusion Proteins, bcr-ablProtein Kinase InhibitorsAniline CompoundsPyrazines

Autor:innen und Institutionen

  • Department of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton T6G 1H9, Alberta, Canada.
  • Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton T6G 2H1, Alberta, Canada.
  • Department of Molecular Genetics and Terry Fox Labs, University of British Columbia, Vancouver V5Z 1L3, British Columbia, Canada.
  • Division of Hematology, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton T6G 2E1, Alberta, Canada.
  • Department of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton T6G 1H9, Alberta, Canada; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton T6G 2H…

Förderung

  • CIHR
  • Canadian Institutes of Health Research
  • Alex's Lemonade Stand Foundation for Childhood Cancer

Zitieren

APA

Ansari, A. S., K C, R., Morales, L. C., Nasrullah, M., Meenakshi Sundaram, D. N., Kucharski, C., Jiang, X., Brandwein, J., & Uludağ, H. (2024). Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.02.018

Vancouver

Ansari AS, K C R, Morales LC, Nasrullah M, Meenakshi Sundaram DN, Kucharski C, et al. Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.02.018

BibTeX
@article{Ansari2024,
  author = {Ansari, Aysha S and K C, Remant and Morales, Luis C and Nasrullah, Mohammad and Meenakshi Sundaram, Daniel Nisakar and Kucharski, Cezary and Jiang, Xiaoyan and Brandwein, Joseph and Uludağ, Hasan},
  title = {Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models},
  journal = {Journal of Controlled Release},
  year = {2024},
  doi = {10.1016/j.jconrel.2024.02.018}
}
Kostenlos starten →